Grifols SA Business Summary

Grifols SA (GRFS) utilizes a vertically integrated business model focused on the collection, fractionation, and purification of human plasma to develop and distribute specialized biological medicines. The company generates revenue primarily through its Biopharma segment—which drove a total of €7.52 billion in 2025 revenue—by selling essential proteins like immunoglobulins, albumin, and alpha-1 antitrypsin. Additional revenue streams flow from its Diagnostic division, specializing in transfusion medicine and clinical testing, and its Bio Supplies unit, which provides biological materials for research and manufacturing. Positioned as a global leader in the plasma-derived therapies market, Grifols competes directly with CSL Behring, Takeda Pharmaceutical, and Octapharma, maintaining a top-three market position while distinguishing itself through a network of nearly 400 donation centers and strategic self-sufficiency projects in Egypt and Canada. Established in 1909 by Dr. Josep Antoni Grífols i Roig, the company is currently managed by CEO Nacho Abia, formerly of Olympus Corporation, and CFO Rahul Srinivasan, who leads the firm’s critical deleveraging and refinancing initiatives. Corporate oversight is provided by Non-Executive Chairperson Anne-Catherine Berner, who succeeded Thomas Glanzmann in 2025 as part of a governance overhaul to decouple family ownership from executive management. The founding Grifols family remains a dominant force, holding approximately 30% of voting rights through entities like Scranton Enterprises B.V., while institutional stability is supported by significant stakes from Norges Bank and Capital Group. This leadership team, which includes Biopharma President Roland Wandeler, is presently focused on margin expansion and reducing the company's leverage ratio from 4.2x to a target of 3.5x by 2027 to restore investor confidence.